Human Microbiome Analysis Market (2026-2036)

The growth of this market is mainly driven by the growing body of evidence linking the human microbiome to gastrointestinal, metabolic, immune, neurological, and oncological conditions, the development and approval of microbiome-based therapeutics, the increasing use of microbiome analysis in clinical diagnostics, and the declining cost of shotgun metagenomic and long-read sequencing. In addition, the use of microbiome biomarkers in drug development, including immuno-oncology, the growth of consumer microbiome testing and personalized nutrition, the development of microbial reference standards, and the use of artificial intelligence (AI) to interpret complex microbiome data are further supporting the growth of this market.

The Human Microbiome Analysis Market, also referred to as the microbiome testing market, microbiome sequencing and analysis market, or human metagenomics market, comprises the services, kits and reagents, instruments, and software used to characterize the composition and function of the microbial communities that live in and on the human body, including the gut, oral cavity, skin, vagina and urogenital tract, and respiratory tract. The market includes sample collection and stabilization kits, nucleic acid extraction kits, library preparation kits, and microbial reference standards; sequencers and other instruments used for 16S rRNA gene sequencing, shotgun metagenomic sequencing, metatranscriptomics, and qPCR; bioinformatics software for taxonomic and functional profiling; and microbiome analysis services, including research sequencing services, clinical microbiome testing, and consumer microbiome tests. The market ecosystem extends from sequencing platform and reagent providers to service laboratories, bioinformatics companies, academic and clinical researchers, microbiome therapeutics developers, pharmaceutical companies, food and nutrition companies, healthcare providers, and consumers.

The market is experiencing strong growth as research increasingly links the microbiome to human health and disease. Changes in microbial communities have been associated with inflammatory bowel disease, irritable bowel syndrome, Clostridioides difficile infection, obesity and type 2 diabetes, cardiovascular disease, allergies and autoimmune conditions, neurological and psychiatric conditions, and responses to cancer immunotherapy. As a result, microbiome analysis has become a standard component of research in gastroenterology, immunology, metabolism, oncology, and neuroscience, generating sustained demand for sequencing and analysis.

The development of microbiome-based therapeutics is an important driver of demand. The U.S. Food and Drug Administration (FDA) approved VOWST, developed by Seres Therapeutics and now owned by Nestlé Health Science, as the first orally administered microbiome-based therapeutic to help prevent recurrence of Clostridioides difficile infection in adults, and in June 2026 Nestlé Health Science agreed to pay USD 25 million to buy out potential VOWST sales-based milestones. Seres Therapeutics continues to develop SER-155, which has Breakthrough Therapy and Fast Track designations for patients undergoing allogeneic hematopoietic stem cell transplantation, and is evaluating it in immune checkpoint inhibitor-related enterocolitis. Microbiome therapeutics developers use microbiome analysis to select patients, confirm engraftment of therapeutic microbes, and identify biomarkers of response, creating demand for clinical-grade sequencing and analysis.

Clinical microbiome testing is also expanding. Microba Life Sciences, an Australian provider of metagenomic gut microbiome testing, reported fiscal year 2026 core testing revenue of AUD 9.0 million, up 92%, on 22,418 tests, up 78%, with an annualized run rate of more than 25,000 tests across Australia and the U.K. by the fourth quarter, and plans to launch its GI Navigator diagnostic in September 2026. Clinical microbiome tests are being used to support the assessment of gastrointestinal conditions and to guide dietary and therapeutic interventions, and the development of validated clinical tests is expected to increase as evidence and reimbursement develop.

Technology advances are improving the resolution and reproducibility of microbiome analysis. Shotgun metagenomic sequencing provides species- and strain-level resolution and functional information that 16S rRNA gene sequencing cannot, and its cost is falling as sequencing becomes cheaper. Long-read sequencing from PacBio and Oxford Nanopore Technologies enables full-length 16S sequencing and the assembly of complete microbial genomes from complex samples. At the same time, standardization is becoming a priority. At ASM Microbe 2026 in June 2026, Zymo Research highlighted microbial community standards, metagenomic reference materials, extraction and library preparation technologies, and microbiome sequencing and multi-omics services, emphasizing the need to reduce lysis bias and improve standardization and reproducibility across microbiome workflows.

The microbiome is also becoming an important consideration in drug development more broadly. Gut microbes can metabolize drugs, influence drug efficacy and toxicity, and modulate immune responses, and pharmaceutical companies are increasingly collecting microbiome samples in clinical trials to understand variability in drug response. Research linking the gut microbiome to the response to immune checkpoint inhibitors has been particularly influential, encouraging the inclusion of microbiome analysis in oncology trials and the development of microbiome-based approaches to improve immunotherapy outcomes. These applications are creating demand for standardized, high-quality microbiome data that can be compared across trial sites and studies.

Consumer and nutrition applications are another source of demand. Consumer microbiome tests offer personalized insights and dietary recommendations, and food, nutrition, and probiotic companies use microbiome analysis to develop and substantiate products. Microba Life Sciences reported that unit sales of its PHGG prebiotic fiber more than doubled in the fourth quarter of fiscal year 2026, reflecting consumer interest in gut health.

At the same time, the market faces challenges related to the lack of standardization, the difficulty of establishing causal links between microbes and disease, and the limited clinical validation and reimbursement of many microbiome tests. The financial pressure on microbiome therapeutics developers, illustrated by Seres Therapeutics projecting cash runway only into the first quarter of 2027, also reflects the challenges of translating microbiome science into products. As a result, providers that can deliver standardized, high-resolution, and clinically meaningful microbiome analysis are expected to capture the largest share of growth over the forecast period.